Results for tag: "Mipomersen"

Mipomersen is a drug used to treat cardiovascular diseases, such as familial hypercholesterolemia (FH). It is a synthetic antisense oligonucleotide that works by blocking the production of apolipoprotein B (ApoB), a protein that helps transport cholesterol in the blood. Mipomersen is administered by subcutaneous injection and is approved for use in adults with FH who are unable to adequately control their cholesterol levels with other lipid-lowering therapies. Mipomersen is a relatively new drug, and its market is still developing. It is currently approved in the United States, Canada, and Europe, and is being studied in other countries. The drug is primarily used to treat FH, but is also being studied for its potential to treat other cardiovascular diseases, such as atherosclerosis and coronary artery disease. Companies in the Mipomersen market include Genzyme Corporation, which developed the drug, and Isis Pharmaceuticals, which holds the rights to market it. Other companies involved in the market include Akcea Therapeutics, which is developing a long-acting version of the drug, and Ionis Pharmaceuticals, which is developing a new drug that works in a similar way. Show Less Read more